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echocardiography (stress echo), exercise stress nuclear scintigra-
phy (stress nuclear), or exercise treadmill test (ETT) study. The
model was developed to evaluate the potential cost savings of
coronary CTA vs. cardiac catheterization in patients who have an
abnormal or non-diagnostic test result. RESULTS: A strategy
utilizing coronary CTA to evaluate patients with an abnormal or
non-diagnostic stress echo, stress nuclear, or ETT study was
cost-saving compared with a conventional strategy of cardiac
catheterization for these patients, up to a CAD prevalence rate
within the study population of 33–72%, depending on the
costs assumptions used in the model. CONCLUSIONS: An
evaluation strategy that uses coronary CTA for the primary
evaluation of patients with abnormal ETT, stress echo, or stress
nuclear test may reduce costs in a patient population with a low
to intermediate prevalence of CAD.
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OBJECTIVES: Acute heart failure (AHF) is life a threatening
disease which includes variable causes and complications. The
aim was to assess clinical characteristics, medication and costs
during hospitalization in patients with AHF. METHODS:
Patients hospitalized in a cardiological dpt. of the Faculty Hos-
pital Brno in January 2005–July2007 were classiﬁed according to
the Guidelines on the diagnosis and treatment of AHF by the
European Society of Cardiology and their medication was fol-
lowed at admission and during the stay. In-patient care costs
include ﬂat rate of admission, stay and medicinal procedures.
(1€ = 25 CZK) RESULTS: In total, 1213 patients (57.5% male,
mean age 72.5 years) with AHF were analyzed. The chronic
medication involved diuretics in 51%, less than half used anti-
platelet drugs, beta-blockers and ACE-I; statins (28.3%), nitrates
(23.6%), digoxin (21.8%). Positive inotropics were indicated in
acute state: norepinephrine (20.4%), dopamine (11.4%), dob-
utamine (10%), epinephrine (9.5%) and levosimendan (4.8%).
New-onset AHF (57%) was more common than decompensated
AHF and was concerned with higher costs. AHF with mild signs
and symptoms prevailed (49.3%), pulmonary oedema and car-
diogenic shock were both in 13%. Total direct in-hospital
expenses were €4.4 million; mean in-patient cost was €3621. The
most expensive were patients in cardiogenic shock with only 3
days of hospitalization (overall mean length-of-stay 8.2 days).
The predictors of high costs were antiarrhythmic interventions
(PM and ICD; 5.9% patients) making up to 21% of total
expenses and revascularizations (coronary angiography followed
by PCI in 31.5% patients) which made 41% of total expenses.
CONCLUSIONS: The treatment of heart failure patients uses
1–2% of health care budget in developed European countries of
which 2/3 are being spent on hospitalizations. AHF hospitaliza-
tion is more frequent as the population ages (62% patients were
more than 70 years old) and is associated with poor prognosis
(in-hospital mortality 14.5%).
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OBJECTIVES: To assess clinical and economic outcomes of PCI
following the commercial availability of drug-eluting stents
(DES). METHODS: We identiﬁed all patients undergoing PCI
from 2000–2002 (pre-DES era) and from 2004—April 31, 2006
(DES era) in a large PCI registry that includes demographic,
clinical, angiographic, procedural and outcome information.
Administrative data were used to estimate length of stay (LOS)
and procedural costs, as well as cardiac hospitalization costs
during year follow-up. We used logistic and Cox proportional
hazard models to estimate the adjusted risk of adverse events
within propensity score stratum and generalized linear modeling
to predict LOS, procedural and follow-up hospitalization costs
by treatment era. RESULTS: We compared 3422 patients from
the DES era (mean age 67, 69% male) and 4303 patients from
the pre-DES era (mean age 67, 70% male). 90% of pre-DES era
patients had bare-metal stents implanted; whereas 83% of DES
era patients had DES. Adverse event rates were similar between
time periods (adjusted odds ratio for in-hospital myocardial
infarction (MI) in DES era: 0.79; 95% CI 0.62, 1.00). During a
median 22 month follow-up, the adjusted incidence of death or
MI was similar between cohorts, but follow up procedures were
reduced in the DES era (hazard ratio for target lesion revascu-
larization in DES era vs. pre-DES era: 0.58; 95% CI 0.50, 0.68).
Models predict a mean LOS reduction of 0.40 days in the DES
era and procedural cost savings of $2053 (95% bootstrapped CI
of adjusted mean difference: -2937, -1197). Follow-up cardiac
hospitalization costs were similar. CONCLUSIONS: In a large
unselected PCI cohort, the introduction of DES was associated
with improved clinical outcomes during follow-up and reduced
in-hospital costs. These data suggest costly new technologies can
be introduced into a general practice setting while maintaining
and improving patient outcomes at an incremental cost savings.
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OBJECTIVES: To determine the cost-effectiveness of endovascu-
lar aneurysm repair (EVAR) versus open surgical repair (OSR)
for non-ruptured, infrarenal abdominal aortic aneurysm (AAA)
in an elective setting. The analysis was conducted for the recent
appraisal of EVAR by the National Institute for Health and
Clinical Excellence in England and Wales. METHODS: A two-
stage cost-utility model was developed from an NHS perspective
to capture the lifetime costs and health outcomes of EVAR. The
model population represented a 70-year old, ﬁt for open surgery,
with an AAA at least 5.5 cm in diameter. A decision-tree model
captured the short-term costs and health outcomes of patients
during the ﬁrst 30-days post-repair, followed by a Markov
model, with monthly cycles during the ﬁrst 24 months and yearly
cycles thereafter, until death. Clinical endpoints included mortal-
ity and complications. Primary data were derived from the EVAR
I randomised controlled trial where reported. To reﬂect current
clinical practice other sources including retrospective patient
data were used. Costs were applied from trial data and national
reference sources. A discount rate of 3.5% was applied to costs
and health outcomes. Univariate and multivariate sensitivity
analyses were performed for all parameters. An incremental cost-
effectiveness ratio (ICER) reﬂecting incremental lifetime costs per
quality adjusted life year (QALY) gained was calculated for the
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